News | December 16, 2021
Syngene extends contract with Amgen till 2026
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
ZY19489 is a novel anti-malarial compound active against all current clinical strains of P. falciparum and P. vivax, including drug resistant strains
While continuing to offer its current breadth of genomic services, Biogazelle will become CellCarta's Center of Excellence for the development of complex genomic biomarker assays
Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology
Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales
Intox is a GLP certified pre-clinical contract research organization with its test facilities in Pune
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
FDA changes inspection classification of the facility to Voluntary Action Indicated
_256_384.jpg)
In Japan, breast cancer is the most common cancer in women, with approximately 92,000 cases of breast cancer diagnosed in 2020
The total cost of the project is estimated at Rs 30 crore
Subscribe To Our Newsletter & Stay Updated
